Fly News Breaks for March 4, 2015
PCRX
Mar 4, 2015 | 08:44 EDT
Brean Capital believes Pacira shares are oversold following the pullback after the company received a Complete Response Letter from the FDA for its nerve block drug, Exparel. The firm feels even if there was a delay in the drug by two years the company can still support a higher valuation. Brean Capital reiterated its Buy rating but lowered its price target to $121 from $135 on Pacira shares.
News For PCRX From the Last 2 Days
There are no results for your query PCRX